ATE473761T1 - METHOD FOR DAMAGE TO CELLS WITH EFFECTOR FUNCTIONS OF ANTI-GFRA1 ANTIBODIES - Google Patents

METHOD FOR DAMAGE TO CELLS WITH EFFECTOR FUNCTIONS OF ANTI-GFRA1 ANTIBODIES

Info

Publication number
ATE473761T1
ATE473761T1 AT05721046T AT05721046T ATE473761T1 AT E473761 T1 ATE473761 T1 AT E473761T1 AT 05721046 T AT05721046 T AT 05721046T AT 05721046 T AT05721046 T AT 05721046T AT E473761 T1 ATE473761 T1 AT E473761T1
Authority
AT
Austria
Prior art keywords
gfra1
antibodies
cells
damage
present
Prior art date
Application number
AT05721046T
Other languages
German (de)
Inventor
Shuichi Nakatsuru
Takashi Iwamoto
Megumi Yoshikawa
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Application granted granted Critical
Publication of ATE473761T1 publication Critical patent/ATE473761T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to the use of cytoxicity based on the effector function of anti-GFRA1 antibodies. Specifically, the present invention provides methods and pharmaceutical compositions that comprise an anti-GFRA1 antibody as an active ingredient for damaging GFRA1-expressing cells using antibody effector function. Since GFRA1 is strongly expressed in breast, gastric, liver, renal or lung cancer cells, the present invention is useful in breast, gastric, liver, renal or lung cancer therapies.
AT05721046T 2005-03-11 2005-03-11 METHOD FOR DAMAGE TO CELLS WITH EFFECTOR FUNCTIONS OF ANTI-GFRA1 ANTIBODIES ATE473761T1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2005/004859 WO2006095446A1 (en) 2005-03-11 2005-03-11 Methods for damaging cells using effector functions of anti-gfra1 antibodies

Publications (1)

Publication Number Publication Date
ATE473761T1 true ATE473761T1 (en) 2010-07-15

Family

ID=34981724

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05721046T ATE473761T1 (en) 2005-03-11 2005-03-11 METHOD FOR DAMAGE TO CELLS WITH EFFECTOR FUNCTIONS OF ANTI-GFRA1 ANTIBODIES

Country Status (7)

Country Link
US (1) US20090155219A1 (en)
EP (1) EP1863530B1 (en)
JP (1) JP4746048B2 (en)
AT (1) ATE473761T1 (en)
DE (1) DE602005022361D1 (en)
ES (1) ES2348161T3 (en)
WO (1) WO2006095446A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016201217A2 (en) * 2015-06-10 2016-12-15 Dae Joon Kim GFR α 1 AS A BIOMARKER FOR CISPLATIN-INDUCED CHEMORESISTANCE AND METASTASIS
WO2017121865A1 (en) * 2016-01-15 2017-07-20 Novo Nordisk A/S Mic-1 receptor and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69724241T2 (en) * 1996-03-14 2004-06-09 Genentech, Inc., South San Francisco GDNF RECEPTOR AND THEIR USE
EP1500400A4 (en) * 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk MEDICAMENT CONTAINING ANTIBODY COMPOSITION
CA2520820A1 (en) * 2003-04-03 2004-10-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Therapeutic products with enhanced ability to immunomodulate cell functions
WO2005029067A2 (en) * 2003-09-24 2005-03-31 Oncotherapy Science, Inc. Method of diagnosing breast cancer
EP1697520A2 (en) * 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites

Also Published As

Publication number Publication date
JP4746048B2 (en) 2011-08-10
WO2006095446A1 (en) 2006-09-14
JP2008532923A (en) 2008-08-21
EP1863530B1 (en) 2010-07-14
ES2348161T3 (en) 2010-11-30
US20090155219A1 (en) 2009-06-18
EP1863530A1 (en) 2007-12-12
DE602005022361D1 (en) 2010-08-26

Similar Documents

Publication Publication Date Title
AR128541A2 (en) METHODS TO MODIFY THE ISOELECTRIC POINT OF ANTIBODIES BY SUBSTITUTING AMINO ACIDS IN THE COMPLEMENTARITY DETERMINATION REGION (CDR)
WO2012064792A3 (en) Protein complexes for antigen binding and methods of use
CY1110337T1 (en) PREGAMPALIN PREPARATION AND RELATED UNIONS
MX357231B (en) Antibody polypeptides that antagonize cd40l.
NZ750005A (en) Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
EA201300239A1 (en) ANTIBODIES TO FAP AND METHODS OF THEIR APPLICATION
NZ602220A (en) Antibodies with ph dependent antigen binding
PH12016501691A1 (en) Antibodies to matrix metalloproteinase 9
WO2012054929A3 (en) Use of human serum albumin to decrease antigenicity of therapeutic proteins
EA200970880A1 (en) STABLE COMPOSITIONS BASED ON ANTIBODIES
EP3255063A3 (en) Antibodies to matrix metalloproteinase 9
WO2013051878A3 (en) Antibody specifically binding to epitope in sema domain of c-met
PE20141151A1 (en) CD27L ANTIGEN BINDING PROTEINS
PH12015501848A1 (en) Binding agents
WO2019056023A3 (en) Claudin6 antibodies and methods of treating cancer
NO20083062L (en) Human monoclonal antibodies to fucosyl GM1 and methods for using anti-fucosyl GM1
MX348432B (en) Sclerostin epitopes.
EA201201533A1 (en) PRLR-SPECIFIC ANTIBODY AND ITS APPLICATIONS
CY1113199T1 (en) STABILIZED GLUCOSEREMPRODUCTION COMPOSITIONS
WO2006116181A3 (en) Regulatory t cell mediator proteins and uses thereof
WO2012064836A9 (en) Methods and compositions for neural disease immunotherapy
WO2011146891A3 (en) High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins
UA111340C2 (en) ANTIBODY THAT SPECIFICALLY Binds to TNF-ALFA OF HUMAN
MX2012012928A (en) Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies.
MX2014010449A (en) Antibodies to matrix metalloproteinase 9.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties